VHPB Centre for Evaluation of Vaccination (CEV) |
Executive Secretary Administrative and Scientific Secretariat |
privacy statement
|
Geneva, Switzerland, May 13-14, 2002
Monday, May 13, 2002
- Meeting Programme - Session 1 Opening and objectives
Chair: André Meheus
09.00 - 09.30
Session 2A HCV infectionChair: Wolfgang Jilg & Daniel Shouval
09.30 - 10.00
The hepatitis C virus 950Kb (.pdf)
Peter Grob (Switzerland)
10.00 - 10.30
Human immune response to hepatitis C virus 893 Kb (.ppt)
Geert Leroux-Roels (Belgium)
10.30 - 11.00
Coffe break
11.00 - 11.30
Laboratory and clinical diagnosis of HCV infection 210 Kb (.pdf)
Jean-Michel Pawlotsky (France)
11.30 - 12.00
Natural history of HCV infection 1,092 Kb (.pdf)
Daniel Lavanchy (WHO, Switzerland)
12.00 - 13.30
Lunch
Session 3 Epidemiology of HCV infection
Chair: Paolo Bonanni & Alessandro Zanetti
13.30 - 14.00
Global epidemiology of HCV infection 1,065 Kb (.pdf)
Daniel Lavanchy (WHO, Switzerland)
14.00 - 14.30
How to collect and evaluate surveillance and epidemiologic data for hepatitis C 499 Kb (.ppt)
Miriam Alter (USA)
Session 5B Country reports
14.30 – 15.00
Health strategy on HCV in The Netherlands 423 Kb (.ppt)
Jan van Hattum (The Netherlands)
15.00 – 15.20
Coffee break
Session 4 Prevention and control of HCV infection
Chair: Yvan Hutin & Harold Margolis
15.20 – 15.50
Public health challenges for controlling HCV infection 107 Kb (.ppt)
Alessandro Zanetti (Italy)
15.50 – 16.20
Development of HCV vaccines: state of the art
Erik D'Hondt (Belgium)
16.20 – 16.50
Prevention of hepatitis C virus infection: achievement through integration into established prevention programmes 360 Kb (.ppt)
Harold Margolis (USA)
16.50 – 17.20
Integrating prevention, control, and therapy for viral hepatitis: the Canadian model 1,317 Kb (.ppt)
David Patrick (Canada)
17.20 – 17.50
HCV injecting drug users: developing indicators of prevalence and responses 1,299 Kb (.ppt)
Lucas Wiessing (EMCDDA, Portugal)
Tuesday, May 14, 2002
Session 2B HCV infection
Chair: Peter Grob & Daniel Lavanchy
09.00 - 09.30
Clinical manifestations of HCV infection 396 Kb (.ppt)
Daniel Shouval (Israel)
09.30 - 10.00
Hepatitis C: therapeutic options 1,781 Kb (.ppt)
Michael Manns (Germany)
10.00 - 10.30
Estimating the global burden of HCV infections associated with unsafe health care injections 408 Kb (.ppt)
Yvan Hutin (WHO, Switzerland)
10.30 - 10.50
Coffee break
Session 5B Country reports
Chair: Selim Badur & Nicole Guérin
10.50 – 11.00
Hepatitis C infection in Turkey 393 Kb (.ppt)
Selim Badur (Turkey)
11.00 – 11.30
Epidemiology, prevention, and control programmes of hepatitis C in Egypt 901 Kb (.ppt)
Mostafa Mohamed (Egypt)
11.30 – 12.00
Surveillance of hepatitis C infections in France 211 Kb (.ppt)
Jean-Claude Desenclos (France)
12.00 – 12.30
Tackling the HCV epidemic in Switzerland 336 Kb (.pdf)
Francesco Negro (Switzerland)
12.30 - 14.00
Lunch
Session 6 Conclusions of the meeting
Chair: Johannes Hallauer & Michael Kew
14.00 - 15.30
Presentation of the VHPB meeting conclusions, including discussion (public health sector: information of the public, recommendations for testing, notification system, target groups; clinical and laboratory sector: collaboration with the public sector, finances)/amendments to existing recommendations (CDC, EASL, NIH, RKI, VHPB, WHO, …)
Johannes Hallauer (Germany) and Michael Kew (South Africa)
15.30
Closing of the meeting